Evaluation of Retinal and Vascular Features in Coats Disease After Intravitreal Injections of Ranibizumab

Optical Coherence Tomography Angiography Findings After Intravitreal Ranibizumab in Patients With Coats Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04310631

Enrollment

Registered

2020-03-17

Start date

2016-01-01

Completion date

2019-12-31

Last updated

2020-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coats Disease

Brief summary

This study evaluates the retinal and vascular features in patients affected by Coats disease under the effects of Ranibizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography

Detailed description

Coats disease is an idiopathic retinal vascular disorder, occurs in young males, and is characterized by retinal telangiactasias, numerous yellowish exudates in the subretinal space, macular edema, hemorrhages and, in advanced end-stage, by exudative retinal detachment. Ranibizumab is a vascular endothelial growth factor antagonist represent an efficacy treatment acting on vascular hyperpermeability. The optical coherence tomography and optical coherence tomography angiography represent novel and non-invasive diagnostic techniques that allow a detailed analysis of retinal and vascular features. The study evaluates the changes in optical coherence tomography and optical coherence tomography angiography parameters at baseline and after three monthly injections of Ranibizumab in Coats disease.

Interventions

DRUGRanibizumab Injection

Ranibizumab Injection (0.5 mg/0.05 ml): Three monthly intravitreal injections

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

19 Years to 30 Years

Healthy volunteers

Inclusion criteria

* age older than 18 years * diagnosis of Coats disease * treatment-naïve with Ranibizumab * absence of other vitreoretinal and vascular retinal diseases * absence of diabetes

Exclusion criteria

* age younger than 18 years * No diagnosis of Coats disease * previous treatments with Ranibizumab * presence of vitreoretinal and vascular retinal diseases * presence of diabetes

Design outcomes

Primary

Measure	Time frame	Description
Study of retinal and vascular features in Coats disease after intravitreal injections of Ranibizumab	Three months	The effectiveness of Ranibizumab injections for treating Coats disease using optical coherence tomography (OCT). The parameters analyzed by OCT were: Central Macular Thickness (micron), Subfoveal Choroidal Thickness (micron)

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026